Fig. 2

miR-432-5p suppresses oncogenicity and targets VGF. (A) HNSCC data. Upper Lt, downregulation of miR-432-5p, and upregulation of VGF expression in tumors. Upper Rt, a reverse correlation lies between VGF expression and miR-432-5p expression in the advanced HNSCC patient subset (T3/T4 and node-positive; n = 166). Lower, GEO dataset of Taiwanese OSCC, Lt, downregulation of miR-432-5p in tumors; Rt, upregulation of VGF in tumors. (B, C) The effects of miR-432-5p mimic in OSCC cells. (B) Induction of miR-432-5p expression with the treatment of mimic. (C) Phenotypes in OSCC cells. Upper, growth. A two-way ANOVA test is performed to evaluate the difference in growth in the exponential growth phase between day 2 and day 4. The original growth curves are shown in Fig. S1. Lower Lt, migration; Lower Rt, invasion. (D) Prediction of targeting of miR-432-5p on the 3’UTR of VGF transcript. (E) Upper, VGF 3’UTR sequences. Blue boxes, primer sites to amplify full 3’UTR sequence. Bold fonts/underline, primers to amplify short 3’UTR sequence. Yellow box, predicted targeted site. Lower, Lt, the alignment of miR-432-5p, wild-type and mutant sequences in the reporters. Green box, wild-type targeted sequences. Red box, mutant sequences. Rt, the differences in the size of full 3’UTR reporter and short 3’UTR reporter. (F) Reporter assays. Lt, full 3’UTR reporter. Rt, short 3’UTR reporter